Danaparoid and activated partial thromboplastin time prolonged Patient Reports February 13, 2012

Danaparoid Side Effects Report #5115443-0
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on Sept 13, 2006. Male patient, 90 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, gastric haemorrhage. Danaparoid dosage: unknown. During the same period patient was treated with GABEXATE MESILATE, MICAFUNGIN, ANTITHROMBIN III, VANCOMYCIN. Patient recovered.

Danaparoid Side Effects Report #5150852-5
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on Oct 30, 2006. Male patient, 90 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, gastric haemorrhage, haemoglobin decreased, red blood cell count decreased, white blood cell count increased. Danaparoid dosage: unknown. During the same period patient was treated with GABEXATE MESILATE, MICAFUNGIN, ANTITHROMBIN III, VANCOMYCIN. Patient recovered.

Danaparoid Side Effects Report #5083999-2
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on Aug 07, 2006. Male patient, 78 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, anaemia, blood lactate dehydrogenase increased, blood potassium increased, blood urea increased, prothrombin time prolonged, subdural haemorrhage. Danaparoid dosage: unknown. During the same period patient was treated with MENATETRENONE, MAGNESIUM OXIDE, FAMOTIDINE, FUROSEMIDE, ALLOPURINOL. Patient died.

Danaparoid Side Effects Report #5029101-4
Danaparoid side effect was reported by a Health Professional from JAPAN on June 07, 2006. Male patient, 78 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, anaemia, blood lactate dehydrogenase increased, blood potassium increased, blood urea increased, platelet count decreased, prothrombin time prolonged, subdural haematoma. Danaparoid dosage: unknown. During the same period patient was treated with MENATETRENONE, MAGNESIUM OXIDE, FAMOTIDINE, FUROSEMIDE, ALLOPURINOL. Patient died.


Danaparoid Side Effects Report #5056237-4
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on Apr 27, 2006. Male patient, 73 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, anaemia, blood fibrinogen increased, blood lactate dehydrogenase increased, blood potassium decreased, fibrin degradation products increased, gamma-glutamyltransferase increased, leukopenia, malnutrition. Danaparoid dosage: unknown. During the same period patient was treated with CYTARABINE, GEMTUZUMAB OZOGAMICIN, ANTITHROMBIN III, CEFOZOPRAN HYDROCHLORIDE, MICAFUNGIN, TRANEXAMIC ACID, BIAPENEM, CLINDAMYCIN PHOSPHATE. Patient recovered.

Danaparoid Side Effects Report #5056239-8
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on July 07, 2006. Male patient, 73 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, anaemia, blood fibrinogen increased, blood lactate dehydrogenase increased, blood potassium decreased, disease progression, fibrin degradation products increased, gamma-glutamyltransferase increased, leukopenia. Danaparoid dosage: unknown. During the same period patient was treated with CYTARABINE, GEMTUZUMAB OZOGAMICIN, ANTITHROMBIN III, CEFOZOPRAN HYDROCHLORIDE, MICAFUNGIN, TRANEXAMIC ACID, BIAPENEM, CLINDAMYCIN PHOSPHATE. Patient recovered.

Danaparoid Side Effects Report #5062425-3
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on July 07, 2006. Male patient, 73 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, anaemia, blood fibrinogen increased, blood lactate dehydrogenase increased, blood potassium decreased, disease progression, fibrin degradation products increased, gamma-glutamyltransferase increased, haemorrhagic diathesis. Danaparoid dosage: unknown. During the same period patient was treated with CYTARABINE, GEMTUZUMAB OZOGAMICIN, ANTITHROMBIN III, CEFOZOPRAN HYDROCHLORIDE, MICAFUNGIN, TRANEXAMIC ACID, BIAPENEM, CLINDAMYCIN PHOSPHATE. Patient recovered.

Danaparoid Side Effects Report #5051297-9
Danaparoid side effect was reported by a Health Professional from JAPAN on July 04, 2006. Male patient, 69 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, haemoglobin decreased, haemorrhage, haemorrhagic diathesis, henoch-schonlein purpura, renal disorder, staphylococcal infection . Danaparoid dosage: unknown. During the same period patient was treated with HEPARIN, DEXPANTHENOL, ALPROSTADIL, MEROPENEM, MINOPHAGEN C, VANCOMYCIN, WARFARIN. Patient was hospitalized. Patient recovered.

Danaparoid Side Effects Report #5121583-2
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on Sept 15, 2006. Male patient, 69 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, haematoma, haemorrhagic diathesis, henoch-schonlein purpura, hepatic function abnormal, renal disorder, staphylococcal infection . Danaparoid dosage: unknown. During the same period patient was treated with ENOXAPARIN, DEXPANTHENOL, ALPROSTADIL, MEROPENEM, MINOPHAGEN C, VANCOMYCIN, HEPARIN, WARFARIN. Patient was hospitalized. Patient recovered.


Danaparoid Side Effects Report #5062431-9
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on July 07, 2006. Male patient, 58 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, anaemia, aspartate aminotransferase increased, blood albumin decreased, blood fibrinogen increased, blood lactate dehydrogenase increased, blood potassium decreased, blood urea increased, fibrin d dimer increased. Danaparoid dosage: unknown. During the same period patient was treated with TRANEXAMIC ACID, DAUNOMYCIN, CYTARABINE, ANTITHROMBIN III, MINOPHAGEN C, CEFTAZIDIME. Patient recovered.

Danaparoid Side Effects Report #5116968-4
Danaparoid side effect was reported by a Health Professional from JAPAN on Sept 13, 2006. Female patient, 49 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, gamma-glutamyltransferase increased. Danaparoid dosage: unknown. During the same period patient was treated with GABEXATE MESILATE, ANTITHROMBIN III, MINOCYCLINE HYDROCHLORIDE, CILASTATIN W, OMEPRAZOLE, NAFAMOSTAT MESILATE, SIVELESTAT, DOPAMINE. Patient died.

Danaparoid Side Effects Report #5153402-2
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on Oct 30, 2006. Female patient, 49 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, condition aggravated, gamma-glutamyltransferase increased, hepatic function abnormal, liver disorder. Danaparoid dosage: unknown. During the same period patient was treated with GABEXATE MESILATE, ANTITHROMBIN III, MINOCYCLINE, CILASTATIN W, OMEPRAZOLE, NAFAMOSTAT MESILATE, SIVELESTAT, DOPAMINE. Patient was hospitalized. Patient died.

Danaparoid Side Effects Report #5056234-9
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on July 07, 2006. Male patient, 43 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, bacteraemia, diarrhoea, enterocolitis, febrile neutropenia, fibrin degradation products increased, platelet count decreased, prothrombin time prolonged, red blood cell count decreased. Danaparoid dosage: unknown. During the same period patient was treated with PLASMA PROTEIN FRACTION, TRANEXAMIC ACID, ETOPOSIDE, NOVANTRONE, ISEPAMICIN SULPHATE, CEFTAZIDIME, ALLOPURINOL. Patient recovered.

Danaparoid Side Effects Report #5017007-6
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on Apr 27, 2006. Male patient, 43 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, bacteraemia, enterocolitis, febrile neutropenia, fibrin degradation products increased, platelet count decreased, prothrombin time prolonged, red blood cell count decreased, white blood cell count decreased. Danaparoid dosage: unknown. During the same period patient was treated with PLASMA PROTEIN FRACTION, TRANEXAMIC ACID, ETOPOSIDE, NOVANTRONE, ISEPAMICIN SULPHATE, CEFTAZIDIME, ALLOPURINOL. Patient recovered.


Danaparoid Side Effects Report #5115458-2
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on Sept 13, 2006. Male patient, 17 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, condition aggravated, hepatic function abnormal. Danaparoid dosage: unknown. During the same period patient was treated with DOPAMINE, CEFPIROME SULPHATE, ANTITHROMBIN III, FAMOTIDINE, METHYLPREDNISOLONE SUCCINATE, ULINASTATIN, OMEPRAZOLE, GABEXATE MESILATE. Patient died.

Danaparoid Side Effects Report #5148279-5
Danaparoid side effect was reported by a Consumer or non-health professional from JAPAN on Oct 30, 2006. Male patient, 17 years of age, was diagnosed with disseminated intravascular coagulation and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, condition aggravated, gastrointestinal haemorrhage, multi-organ failure. Danaparoid dosage: unknown. During the same period patient was treated with DOPAMINE, CEFPIROME SULPHATE, ANTITHROMBIN III, FAMOTIDINE, METHYLPREDNISOLONE SUCCINATE, ULINASTATIN, OMEPRAZOLE, GABEXATE MESILATE. Patient died.

Danaparoid Side Effects Report #6029416-7
Danaparoid side effect was reported by a Physician from CANADA on Dec 22, 2008. Female patient, 64 years of age, was diagnosed with prophylaxis and was treated with Danaparoid. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, adrenal disorder, adrenal haemorrhage, adrenal insufficiency, amnesia, blood lactate dehydrogenase increased, calcinosis, cerebral ischaemia, deep vein thrombosis . Danaparoid dosage: unknown. During the same period patient was treated with FONDAPARINUX, ARGATROBAN, DALTEPARIN. Patient recovered.